Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GNC immune defense

This article was originally published in The Tan Sheet

Executive Summary

Preventive Nutrition Immune Defense product will be discounted 50% through the end of the year for customers age 50 and over, GNC announces Oct. 6. Immune Defense, which includes a blend of berry extracts, zinc and vitamin C, is "designed to support the body's immune cell function and boost its natural resistance," according to the firm. The retail chain also will offer free educational information on cold and flu prevention at its 4,800 retail locations as well as on its 1website beginning in November...

You may also be interested in...



Bayer Gives Consumer Health A Star, But Plans $1.76Bn In Annual Overall Cost Reductions

Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.

Moderna CEO Bancel Pushes Back On Trump Debate Comments On COVID-19 Vaccine

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.

Major Milestone For Diurnal As FDA Approves Alkindi

The US green light for Alkindi is a big step for the UK biotech in its bid to become a world-leading specialty endocrinology business.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel